<?xml version="1.0" encoding="UTF-8"?>
<p>where 
 <italic>V</italic>
 <sub>0</sub> is the initial viral load level, 
 <italic>R</italic>
 <sub>0</sub> is the basic reproductive number (see below), 
 <italic>δ</italic> is the loss rate of infected cells, 
 <italic>C</italic>
 <sub>ave</sub> is the average drug concentration (as predicted by the PK model), and EC
 <sub>50</sub> is the drug concentrations leading to 50% efficacy in reducing the basic reproductive number. Using this simple model to fit the viral load obtained in untreated NHPs and in those treated with 100 mg/kg b.i.d. (with 
 <italic>δ</italic> fixed to 1/day to ensure parameter identifiability), we estimated 
 <italic>R</italic>
 <sub>0</sub> to about 3.25 and EC
 <sub>50</sub> to 334 µg/mL. Then, we plugged into the model the predicted concentrations obtained with doses of 150 and 180 mg/kg b.i.d. (administered prophylactically) to predict that median reduction of 3–4 log
 <sub>10</sub> RNA/mL at D7 could be obtained with these dosing regimens compared with untreated animals (
 <bold>Table </bold>
 <xref rid="psp412510-tbl-0001" ref-type="table">
  <bold>1</bold>
 </xref>
 <bold>:</bold> Prediction for the two subsequent experiments). Such reduction could significantly extend survival, as observed in rhesus macaques treated with the polymerase inhibitor galidesivir (BCX‐4430), where all treated animals that had a peak viremia below 10
 <sup>6</sup> RNA copies/mL survived the infection.
 <xref rid="psp412510-bib-0045" ref-type="ref">
  <sup>45</sup>
 </xref>
</p>
